Healx is leveraging AI technology to repurpose drugs to treat the planet’s rarest diseases.
The company raised $56 million in a Series B round in October – backed by Japanese and European investors – taking its haul in the last 12 months to around $66m.
The Series B was led by one of Europe’s largest VC firms Atomico which is headquartered in London with offices in Beijing, Istanbul, São Paulo, Stockholm and Tokyo. Its founder and CEO is Niklas Zennström, a serial entrepreneur who co-founded Skype and Kazaa.
Tokyo-based Global Brain and btov Partners which has offices in Berlin, Luxembourg, Munich and St. Gallen in Switzerland joined the round.
All previous investors including Balderton Capital, Amadeus Capital Partners and Cambridge UK serial entrepreneur Jonathan Milner also participated. The money will be used to develop the company’s therapeutic pipeline and launch its unique global Rare Treatment Accelerator programme.
Healx’s mission is to advance 100 rare disease treatments towards the clinic by 2025. Healnet, Healx’s AI platform, delivers data-driven treatment predictions, which shortens the discovery-to-clinic timeline to as little as 24 months.